Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion. #MPN | Oncology Brothers Naveen Pemmaraju, MD

cancernetwork.com/view/adverse-e…

Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning. #pcsm | James Yu
Julian Hong

cancernetwork.com/view/ai-use-in…

Join PER on Friday, May 31st at the Annual Oncology meeting in Chicago for their Lung Cancer Tumor board on emerging data in SCLC! Listen to expert faculty as they Explore emerging strategies for treating SCLC & more! Learn more here: ow.ly/59y850RSZNt

An expert on myelofibrosis discusses anemia and splenomegaly management practices for patients with myelofibrosis. #MPN | Naveen Pemmaraju, MD Oncology Brothers

cancernetwork.com/view/managing-…

.U.S. FDA updated the PDUFA date for subcutaneous nivolumab in solid tumors to December 29, 2024.

cancernetwork.com/view/fda-accep…

Of 7 studies that reported on the outcomes of unilateral and bilateral mastectomy, 3 highlighted increased complication rates with bilateral mastectomy, with ORs ranging from 1.5 (95% CI, 1.0-2.3) to 2.1 (95% CI, 1.3-3.5). #bcsm

cancernetwork.com/view/bilateral…

The use of the investigational fluorophore Illuminare-1 elicited minimal complications in a small cohort of patients with prostate adenocarcinoma who were scheduled to undergo minimally invasive radical prostatectomy. #pcsm | Tim Donahue

cancernetwork.com/view/novel-flu…

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care. #mmsm | Donna Catamero Beth Faiman PhD Tiffany Richards, PhD, ANP-BC, AOCNP

cancernetwork.com/view/apps-focu…

📖 Fumiko Ladd Chino, MD spoke about the recently published study linking talcum powder to ovarian cancer. #gyncsm

Read the full interview here ⬇️
cancernetwork.com/view/sister-st…

Naveen Pemmaraju, MD, gives a comprehensive overview of JAK inhibitors available for the treatment of patients with myelofibrosis. #MPN | Oncology Brothers Naveen Pemmaraju, MD

cancernetwork.com/view/jak-inhib…

A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis. #hematology | Naveen Pemmaraju, MD Oncology Brothers

cancernetwork.com/view/supportiv…

Clinically effective and safe outcomes occurred in patients with previously treated, locally advanced or metastatic, estrogen receptor–positive, HER2-negative breast cancer when combining vepdegestrant with palbociclib. #bcsm | Erika Hamilton, MD ESMO - Eur. Oncology

cancernetwork.com/view/vepdegest…

Regarding the TITAN-TCC approach, 48% (Clopper-Pearson exact 90% CI, 0.34-0.61; 1-sided P <.001) of patients in first-line cohort 1 achieved a response, and 7% had a complete response. #blcsm | Marc-Oliver Grimm

cancernetwork.com/view/nivolumab…

Hans Hammers, MD, PhD, and his colleagues sat down to discuss treatment options for those with advanced renal cell carcinoma. #kicsm | Hans Hammers

cancernetwork.com/view/learning-…

Biomarkers associated with HER2 appeared to confer improved objective response rates among patients with HER2-positive gastric cancer who received T-DXd. #gicsm | Kohei shitara

cancernetwork.com/view/her2-rela…

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ QOL. #mmsm | Rahul Banerjee, MD, FACP

cancernetwork.com/view/the-impac…

Nivolumab monotherapy produced a major pathological response rate of 27% and an objective radiographic response in 10%, with corresponding values of 30% and 27% in the nivolumab plus relatlimab combination arm. #NSCLC

cancernetwork.com/view/nivolumab…

The BLA is intended to support the use of tabelecleucel in those who have received at least 1 prior line of therapy. #hematology | U.S. FDA FDA Oncology

cancernetwork.com/view/developer…

The FDA has granted BTD to inavolisib when administered with palbociclib and fulvestrant for adults with HR+, HER2-, locally advanced or metastatic breast cancer harboring PIK3CA mutations following prior adjuvant endocrine therapy. #bcsm | U.S. FDA

cancernetwork.com/view/inavolisi…

Ted A. James, MD, MHCM, FACS, spoke about integrating artificial intelligence into oncology care. #medtwitter #artificiallntelligence | Ted James PER

cancernetwork.com/view/exploring…